Supplement Industry Pushes FDA for New Ingredient Approval Process

↕

  //food-wine.news-articles.net/content/2026/03/28 .. hes-fda-for-new-ingredient-approval-process.html
  Published in Food and Wine on Saturday, March 28th 2026 at 13:43 GMT by WTVD
      Locale: UNITED STATES

RALEIGH, N.C. - The dietary supplement industry is mounting a significant campaign to persuade the Food and Drug Administration (FDA) to establish a streamlined approval process for new ingredients, with a particular focus on peptides and other compounds currently excluded from legal supplement formulations. This push comes amidst claims that the existing regulatory landscape is hindering innovation and denying consumers access to potentially beneficial health products.

For decades, the FDA has maintained a cautious stance on many ingredients used in dietary supplements, a position rooted in concerns about safety and efficacy. While the 1994 Dietary Supplement Health and Education Act (DSHEA) established a framework for regulating supplements, it placed the burden of proof on the FDA to demonstrate harm after a product is on the market - a reactive rather than proactive approach. Now, supplement manufacturers argue this system is outdated and ill-equipped to handle the rapid advancements in nutritional science, specifically regarding ingredients like peptides.

"It's a very frustrating situation," explains Daniel Fabricant, CEO of the Natural Products Association, a leading industry trade group. "We've got ingredients with a growing body of scientific research supporting their benefits, yet they remain inaccessible to consumers. It's not about eliminating regulations; it's about creating a viable pathway for bringing these innovations to market."

Peptides, short chains of amino acids that act as building blocks for proteins, represent a key area of contention. Promoted for their potential roles in muscle recovery, skin health, cognitive function, and even anti-aging, peptides are gaining traction in research and consumer interest. However, the FDA's current regulations, largely designed for traditional food ingredients and single-molecule compounds, don't readily accommodate the complexities of peptide structures and sourcing. The agency struggles to categorize and approve them within the existing framework.

The industry's request isn't merely for peptides. It encompasses a broader range of "novel" ingredients - compounds that haven't traditionally been consumed in the food supply or lack a clear history of safe use. This could include certain types of polyphenols, specialized carbohydrates, and even bioengineered nutrients. Manufacturers propose a system of pre-market notification, where companies would submit data on safety and manufacturing quality before launching a new ingredient, offering the FDA an opportunity for review.

However, the FDA isn't yielding easily. Several key challenges underpin their resistance. Labeling accuracy is a significant hurdle. Peptides can be derived from various sources - plants, animals, and increasingly, through synthetic manufacturing. Clearly and accurately identifying the source and specific composition of peptides on product labels poses a technical and logistical problem, crucial for allergen control and traceability. Moreover, the sheer diversity of peptide structures makes standardized testing and quality control more difficult.

Perhaps more importantly, the FDA emphasizes the need for robust safety data, particularly regarding long-term effects. While preliminary studies may suggest potential benefits, the agency requires comprehensive evidence of safety, including potential interactions with medications and effects on vulnerable populations. "We have to be cautious and make sure we're protecting consumers," states Dr. Steven Galson, a former FDA director. "We need a thorough understanding of the safety profile of these ingredients before they become widely available. The potential for unforeseen consequences is real."

The debate between the industry and the FDA represents a fundamental tension: fostering innovation versus ensuring consumer protection. Supplement manufacturers contend that a rigid regulatory system stifles research and development, forcing companies to either operate in a legal gray area or move production overseas to countries with less stringent regulations. They also argue that consumers are increasingly sophisticated and actively seeking out innovative health products.

The FDA, however, points to a history of problematic supplements - adulterated products, mislabeled ingredients, and unsubstantiated health claims - as justification for its cautious approach. They fear that a relaxed regulatory environment could open the door to unsafe products and erode public trust.

Finding a middle ground will require a collaborative effort. Potential solutions could include a tiered approval process, where ingredients with a strong history of safe use require less rigorous testing than entirely novel compounds. Standardized testing protocols for peptides and other complex ingredients would also be essential. Furthermore, increased funding for the FDA's supplement division could enable the agency to more effectively evaluate new ingredients without creating excessive delays. The future of the dietary supplement industry, and consumer access to innovative nutritional products, hinges on this crucial negotiation.